Alnylam Pharmaceuticals (Nasdaq: ALNY) has committed up to USD 2 billion to embed generative AI into its siRNA discovery engine, entering a strategic collaboration agreement with Palo Alto-based Inceptive Nucleics, Inc. that pairs the RNAi pioneer's two decades of proprietary experimental data with foundation models built by the co-inventor of the Transformer architecture. The Alnylam Inceptive collaboration carries USD 30 million in upfront consideration — structured as a combination of cash and an equity purchase in privately held Inceptive — with the remainder contingent on preclinical, regulatory, and commercial milestones. No specific drug candidates, targets, or indications are named.
The upfront payment is modest relative to the headline value, with the USD 30 million representing roughly 1.5% of the USD 2 billion ceiling — a structure consistent with platform-level discovery collaborations where back-loaded milestones reflect the multi-program, multi-year scope of the work. Royalty terms were not disclosed, which is typical for AI services arrangements where the platform provider is compensated through milestones rather than downstream revenue participation.
Deal context
Inceptive, founded in 2021 and backed by Andreessen Horowitz, NVIDIA's NVentures, S32, and Obvious Ventures, builds what it describes as generative AI foundation models trained on heterogeneous biological sequence data. Inceptive applies that same architectural logic to biological sequences — treating RNA and peptide molecules as a language with learnable grammar — to design novel siRNA candidates predicted to have optimized potency, specificity, and stability.
The deal arrives as Alnylam has been accelerating its external partnering activity. In March 2026, the company entered a research collaboration with Tenaya Therapeutics (Nasdaq: TNYA) worth up to USD 1.13 billion to validate cardiovascular gene targets for RNAi drug development — a deal that sourced discovery biology from outside rather than AI capabilities. Earlier the same month, Alnylam struck a multi-year genomic data agreement with Helix to access phenotyped cohort data for target identification. The Inceptive deal adds a third distinct external capability — generative AI-powered molecular design — completing what appears to be a deliberate effort to build a data-to-candidate pipeline from multiple external inputs simultaneously.